LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Ventyx Biosciences Inc

Cerrado

2.34 -5.26

Resumen

Variación precio

24h

Actual

Mínimo

2.31

Máximo

2.48

Métricas clave

By Trading Economics

Ingresos

1.9M

-27M

BPA

-0.39

Empleados

81

EBITDA

2.4M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+365.31% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

58M

161M

Apertura anterior

7.6

Cierre anterior

2.34

Ventyx Biosciences Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

23 sept 2024, 12:43 UTC

Principales Movimientos del Mercado

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Comparación entre iguales

Cambio de precio

Ventyx Biosciences Inc Esperado

Precio Objetivo

By TipRanks

365.31% repunte

Estimación a 12 meses

Media 11.4 USD  365.31%

Máximo 21 USD

Mínimo 2 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ventyx Biosciences Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

8 ratings

5

Comprar

3

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.